10-Q: Cypherpunk Pivots to Zcash, Secures $58.8M, New Leadership

Cypherpunk Technologies Inc. (formerly Leap Therapeutics) has completed a strategic pivot to a digital asset treasury strategy focused on Zcash, raising $58.8 million and appointing new digital asset-focused executives.

Summary

• The company renamed from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc. (effective November 12, 2025), with its Nasdaq ticker changing from LPTX to CYPH (anticipated November 13, 2025).
• A strategic pivot to a digital asset treasury strategy has been completed, primarily focused on acquiring and holding Zcash (ZEC) tokens.
• Biopharmaceutical operations (sirexatamab, FL-501) will continue under a new wholly-owned subsidiary, Leap Therapeutics, Inc., following a wind-down of R&D activities and a 75% workforce reduction.
• An October 2025 Private Placement was completed, raising approximately $57.0 million in net proceeds, led by Winklevoss Treasury Investments, LLC.
• Subsequent to the quarter-end, 203,775 ZEC tokens were purchased for an aggregate of $50.0 million at a weighted average cost of $245.37 per token.
• Khing Oei was appointed as Chairman of the Board and Will McEvoy as a Board member and Chief Investment Officer, effective November 11, 2025.
• The net loss for the nine months ended September 30, 2025, was $35.381 million, an improvement from $52.124 million in the same period of 2024, primarily due to reduced R&D expenses.
• Cash and cash equivalents were $9.686 million as of September 30, 2025, significantly down from $47.249 million at December 31, 2024, but supplemented by the recent private placement.
• Stockholders will vote on proposals including increasing authorized shares, a reverse stock split, and adopting a new equity incentive plan at a special meeting on December 15, 2025.

Sentiment

Score: 4

Explanation: The company has secured significant new funding and pivoted to a new strategy, which could be seen as positive for survival. However, the pivot involves exiting a core business, incurring restructuring costs, and entering a highly volatile and uncertain digital asset market with substantial regulatory and operational risks. The long-term viability and profitability of the new strategy are highly speculative, leading to a cautious, slightly negative sentiment.

Positives

• Successful completion of a $58.88 million private placement, significantly bolstering capital.
• Strategic pivot to a digital asset treasury strategy, potentially opening new growth avenues.
• Appointment of experienced digital asset executives (Khing Oei as Chairman, Will McEvoy as CIO and Board member).
• Reduced net loss for the nine months ended September 30, 2025 ($35.381 million) compared to the same period in 2024 ($52.124 million).
• Reduced research and development expenses ($24.695 million in 9M 2025 vs. $44.099 million in 9M 2024) due to R&D wind-down, conserving cash.
• Positive final clinical data from Part B of the DeFianCe study for sirexatamab in DKK1-high CRC patients, showing statistically significant benefits in overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Negatives

• Significant decrease in cash and cash equivalents to $9.686 million as of September 30, 2025, prior to the private placement.
• Accumulated deficit increased to $502.752 million as of September 30, 2025.
• Wind-down of biopharmaceutical R&D activities and a 75% workforce reduction indicate a significant shift away from the previous core business.
• Incurred $4.527 million in restructuring charges during the nine months ended September 30, 2025.
• Interest income decreased significantly to $0.8 million (9M 2025) from $2.5 million (9M 2024) due to lower average cash balances.

Risks

• Inability to successfully implement the new digital asset treasury strategy or operate ZEC-related activities profitably.
• Exposure to significant operational risks due to the rapidly evolving Zcash ecosystem, including upgrades, protocol changes, and reliance on third-party service providers like Gemini.
• High volatility of ZEC price, which may adversely influence financial results (unrealized gains/losses) and the market price of listed securities.
• Limited experience in investing in and managing digital assets, and reliance on a single custodian (Gemini) for ZEC, exposing the company to cybersecurity risks, loss of private keys, or custodian insolvency.
• Risk of inadvertently engaging in transactions with or for the benefit of prohibited persons due to the pseudonymous nature of blockchain transactions and OFAC sanctions.
• The cryptography used to enhance Zcash privacy (zk-SNARKs) is new and could fail, or be used for illicit activities, leading to increased regulatory scrutiny or delisting from exchanges.
• Potential compromise of Zcash network security by emerging technologies like artificial intelligence and quantum computing.
• Significant legal, commercial, tax, and regulatory uncertainty surrounding ZEC and other digital assets, including potential reclassification as a security or commodity pool.
• EU regulations, effective July 1, 2027, will prohibit transactions involving anonymous wallets and privacy-focused digital assets such as ZEC.
• The company is not subject to legal and regulatory obligations that apply to investment companies (mutual funds, ETPs) or investment advisers, meaning stockholders lack certain protections.
• Changes in regulatory interpretations could require registration as a money services business or money transmitter, leading to increased compliance costs or operational shutdowns.
• The availability of spot ETPs for digital assets may adversely affect the market price of the company's listed securities.
• Emergence or growth of other digital assets (stablecoins, CBDCs) could negatively impact ZEC price.
• Concentration of voting power among Winklevoss Capital and affiliates could lead to the company becoming a 'controlled company' under Nasdaq rules, reducing independent director influence.
• The common stock may trade at a substantial premium or discount to the value of ZEC held, and its price may be more volatile than ZEC.
• Inability to raise additional capital on acceptable terms could compromise the digital asset treasury strategy.
• Limited ability to time ZEC purchases, exposing the company to market declines.
• A significant decrease in the market value of digital asset holdings could adversely affect the ability to satisfy financial obligations.
• Complex valuation controls and benchmark dependence may lead to restatements or control deficiencies.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future. It believes its current cash and cash equivalents, combined with $7.0 million from the October 2025 Private Placement allocated for operations, will fund operating expenses for at least the next 12 months. The company will likely seek additional funding through public or private equity financings or government programs, and through collaboration agreements or licenses for its biopharma subsidiary. An update on the next steps in development and the registrational pathway for sirexatamab in CRC is expected in the first quarter of 2026. Stockholders will vote on proposals to increase authorized shares, effect a reverse stock split, and adopt a new equity incentive plan at a special meeting on December 15, 2025.

Management Comments

• "We believe that privacy-protecting assets and related technologies will be critical in an increasingly digital world."
• "We intend to acquire and hold ZEC as our primary digital asset and to be an active participant in the Zcash community."
• "We are now in the process of engaging with regulatory agencies in the United States and Europe over the registrational pathway for sirexatamab in CRC."
• "We are also working with a leading diagnostics research laboratory to optimize the DKK1 biomarker diagnostic test that could be used to identify CRC patients with poor prognosis and to select patients for treatment with sirexatamab."
• "We expect to provide an update on the next steps in development and on the registrational pathway in the first quarter of 2026."

Industry Context

The company's pivot from biopharmaceuticals to a digital asset treasury strategy, specifically focusing on Zcash (ZEC), is a significant and unusual shift. While other public companies have adopted Bitcoin treasury strategies (e.g., MicroStrategy), a focus on a privacy coin like Zcash is less common and introduces unique regulatory and technical risks. The biopharmaceutical industry continues to see high R&D costs and long development cycles, which likely contributed to Leap Therapeutics' decision to wind down its primary drug development programs. The digital asset space, particularly privacy coins, faces increasing regulatory scrutiny (e.g., EU regulations on anonymous wallets), making this a high-risk, high-reward strategy. The involvement of Winklevoss Capital, known for its crypto ventures (Gemini), provides some industry credibility to the new direction.

Comparison to Industry Standards

• The strategic pivot to a digital asset treasury strategy, particularly with a focus on Zcash, is a novel approach for a publicly traded company, making direct comparisons to traditional industry standards difficult.
• In the biopharmaceutical sector, the wind-down of R&D programs like sirexatamab and FL-501, despite some positive clinical data for sirexatamab, indicates a failure to secure sufficient funding or a strategic decision to exit a capital-intensive industry. This contrasts with successful biopharma companies that typically advance promising candidates through later-stage trials and commercialization.
• Compared to other public companies that have adopted digital asset treasury strategies (e.g., MicroStrategy with Bitcoin), Cypherpunk's focus on Zcash introduces additional risks related to privacy-enhancing features and potential regulatory pushback, as highlighted by the EU's upcoming prohibition on anonymous wallets.
• The appointment of Khing Oei (Founder and CEO of Treasury, formerly Eyck Capital) and Will McEvoy (Principal at Winklevoss Capital) brings significant experience from the digital asset and investment management sectors, aligning with the new strategy, but their expertise is not directly comparable to traditional biopharma leadership.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of this report, the company is not currently a party to any material legal proceedings.

Related Party Transactions

• Winklevoss Treasury Investments, LLC (Winklevoss Capital) is the Lead Investor in the October 2025 Private Placement.
• Gemini Space Station, LLC, a subsidiary with which the company entered into a Digital Asset Purchase and Sale Agreement for ZEC tokens, is an affiliate of Winklevoss Capital.
• Khing Oei, the new Chairman of the Board, is the sole owner and director of CoinXit Ltd., with which the company entered into a Consulting Agreement and granted RSUs.
• Eli Lilly and Company (Lilly) is a shareholder and party to a license agreement with the company.

Stakeholder Impact

• Shareholders face significant dilution from recent private placement and potential future capital raises/reverse stock split. High volatility and new risks are associated with the digital asset strategy. There is potential for long-term value creation if the digital asset strategy is successful, but also significant risk of loss.
• Employees experienced a significant workforce reduction (75%) in the biopharma segment. New hires and equity awards are being made for digital asset-focused management.
• Customers (Biopharma) will not see new products from the original pipeline due to the wind-down of R&D programs.
• Creditors have improved liquidity from the private placement, but future operations are dependent on successful execution of a high-risk strategy and potential further funding.
• Regulatory Authorities will likely increase scrutiny due to the pivot to digital assets, especially a privacy coin like Zcash, and the associated legal and compliance uncertainties.

Next Steps

• Special meeting of stockholders on December 15, 2025, to vote on proposals including increasing authorized shares, a reverse stock split, and adopting a new 2025 Equity Incentive Plan.
• Engage with regulatory agencies in the United States and Europe over the registrational pathway for sirexatamab in CRC.
• Work with a leading diagnostics research laboratory to optimize the DKK1 biomarker diagnostic test.
• Provide an update on the next steps in development and the registrational pathway for sirexatamab in the first quarter of 2026.
• Continue to acquire and hold ZEC as its primary digital asset and participate in the Zcash community.
• Likely seek additional funding through public or private equity financings or government programs, and through collaboration agreements or licenses for its biopharma subsidiary.

Key Dates

Recommendation

The company is undergoing a radical strategic transformation from a biopharmaceutical entity to a digital asset treasury company focused on Zcash. While the recent capital raise provides a much-needed liquidity injection and the new management brings relevant expertise, the inherent volatility and significant regulatory uncertainties surrounding privacy-focused digital assets like ZEC present substantial risks. The wind-down of the biopharma pipeline, despite some positive clinical data, marks a complete departure from its historical business. Investors should 'hold' to observe the execution of this new, high-risk strategy and await further clarity on regulatory developments and the company's ability to navigate the volatile digital asset market. A 'buy' or 'sell' would be premature given the magnitude of the pivot and the speculative nature of the new business model.

Keywords

Zcash, ZEC, Digital Assets, Cryptocurrency, Blockchain, Biopharmaceutical, Cancer Therapy, Sirexatamab, DKN-01, Winklevoss Capital, Private Placement, Corporate Restructuring, SEC Filing, 10-Q, Financial Reporting, Nasdaq, Corporate Governance, Risk Management, Biotech, Privacy Coin